A detailed history of Public Investment Fund transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Public Investment Fund holds 354,385 shares of BGNE stock, worth $68.8 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares
354,385
Holding current value
$68.8 Million
% of portfolio
0.32%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $51 Million - $79.6 Million
354,385 New
354,385 $79.6 Million
Q3 2023

Nov 14, 2023

BUY
$179.87 - $225.13 $6.6 Million - $8.26 Million
36,700 Added 11.55%
354,385 $63.7 Million
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $41.9 Million - $64.2 Million
317,685 New
317,685 $42.8 Million
Q4 2021

Feb 14, 2022

SELL
$248.56 - $389.34 $44.2 Million - $69.2 Million
-177,704 Reduced 35.87%
317,685 $86.1 Million
Q3 2021

Nov 15, 2021

BUY
$249.6 - $403.14 $124 Million - $200 Million
495,389 New
495,389 $180 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $20.1B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Public Investment Fund Portfolio

Follow Public Investment Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Public Investment Fund, based on Form 13F filings with the SEC.

News

Stay updated on Public Investment Fund with notifications on news.